New Experimental Drug Shows Promise in Reducing Cardiovascular Risk
Eli Lilly’s lepodisiran, an experimental drug targeting high levels of lipoprotein(a), or Lp(a), has shown remarkable results in reducing this cholesterol component that can increase the risk of cardiovascular disease. The Phase 2 trial data published over the weekend found a 94% drop in Lp(a) levels among participants with a genetic predisposition to high Lp(a). … Read more